Navigation Links
KNOW Bio Respiratory Has New Name, Novoclem Therapeutics, New Antimicrobial Drug Candidate for Lung, Respiratory Infections
Date:4/11/2017

DURHAM, N.C., April 11, 2017 /PRNewswire/ -- Novoclem Therapeutics, a subsidiary of private life science technology company KNOW Bio, LLC, today unveiled its new name and announced that in-vitro studies show its lead drug candidate, a nitric oxide releasing biopolymer, eradicates nine of the most common and serious pathogens prevalent in severe lung infections.

Formerly known as KNOW Bio Respiratory, Novoclem Therapeutics' new name better reflects the company's strong position as a purpose built, development stage pharmaceutical company dedicated to leading a new fight against antibiotic resistant pathogens. 

"The name Novoclem means 'the new fight' and it captures our company's bold mission and innovative spirit to challenge the status quo of current inhaled antibiotic therapy. Our mission is to arm patients with therapies that treat resistant bacteria and enable them to breathe better and live more fully," said Anne Whitaker, CEO and President of Novoclem Therapeutics. "We are committed to bring to market breakthrough antimicrobial therapies that will address the growing need of patients with severe lung diseases like cystic fibrosis. Based on initial studies, we believe our new drug candidate will do just that."   

The in-vitro studies, conducted by researchers at Southern Research Institute, [an independent, third-party laboratory] showed that the drug candidate was active against the following pathogens, several of which are a significant public health threat according to the FDA:  

  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Methicillin-sensitive Staphylococcus aureus (MSSA)
  • Pseudomonas aeruginosa
  • Burkholderia cepacia
  • Mycobacterium Avium-Intracellulare Complex (MAC)
  • Mycobacterium abscessus
  • Achromobacter xylosoxidans
  • Stenotrophomonas maltophilia

"The findings suggest that Novoclem's product has great clinical utility across a range of difficult-to-treat infections," said Dr. Mark Schoenfisch, Professor of Chemistry at the University of North Carolina at Chapel Hill, co-inventor of the nitric oxide-releasing biopolymer platform technology and Novoclem's Chief Science Officer. "That's why we believe our technology will be able to break down the bacterial drug resistance barrier and soon we'll be able to effectively treat many types of lung infections."

About Novoclem Therapeutics

Novoclem Therapeutics was created to develop nitric oxide solutions for cystic fibrosis and other respiratory diseases. It is initially focused on developing a treatment for severe bacterial lung infections in CF patients. The technology is effective against both antibiotic-resistant Pseudomonas aeruginosa, which is present in the lungs of approximately 60 percent of patients with CF, and Mycobacterium abscessus, a growing threat to CF patients. The company anticipates submitting an Investigational New Drug application and initiating First in Human clinical trials in early 2018. More info available at www.novoclem.com.   

About KNOW Bio LLC

KNOW Bio, LLC was created to develop and optimize the company's proprietary and versatile nitric oxide platform. The technology can be delivered as a drug in a variety of doses and release time frames, which makes the therapeutic areas that will likely be impacted by this platform immense. 

Forward-looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.  Actual results might differ materially from those explicit or implicit in the forward-looking statements.  Important factors that could cause actual results to differ materially include:  risks associated with the drug development process; reliance on key personnel; the early stage of our business; competition; and other risks described in other Company press releases and presentations.  KNOW Bio assumes no obligation and does not intend to update these forward-looking statements, except as required by law. 

Contact Info:
Ray Young
Razor Sharp PR
(512) 633-6855
ray@razorsharppr.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/know-bio-respiratory-has-new-name-novoclem-therapeutics-new-antimicrobial-drug-candidate-for-lung-respiratory-infections-300438000.html


'/>"/>
SOURCE Novoclem Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Research and Markets - Global Respiratory Diagnostic and Monitoring Device Market, 2022: Key Players are General Electric, Masimo, Hamilton Medical, Koninklijke Philips & Medtronic
2. Research and Markets - Global $30.2 Billion Respiratory Complications Therapeutics Market to 2022: Pfizer is Expected to Maintain its Position as Market Leader
3. Moderate Growth in $26 Billion Respiratory Devices: Report
4. The Global Respiratory Inhalers Market 2017-2027
5. Global Respiratory Care Devices Market to Reach $38.2 Billion by 2025 - Huge Growth Opportunity in Asia Pacific Region - Research and Markets
6. Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
7. Pulmonary/ Respiratory Drug Delivery Market by Formulation, Device Type, Canister, End User, Applications - Forecasts to 2021
8. Pulmonary/Respiratory Drug Delivery Market Worth 52.37 Billion USD by 2021
9. New Study Published in Lancet Respiratory Medicine Highlights QIAGENs QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants
10. Global Respiratory Care Devices Market Expected to Reach $21,300 Million by 2022 - Allied Market Research
11. Pulmonary Drug Delivery Devices Market to Reach US$43.05 Billion by 2024: Rising Prevalence of Respiratory Disorders to Drive Growth, Notes TMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... WAYNE, N.J. , June 16, 2017 Datascope Corp. ... sold by Datascope Corp. for a potential electrical test failure code.     ... PRODUCT PART NUMBER ... CS100 IABP CS300 IABP ... ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that the U.S. Food and Drug Administration ... June 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning ... manufacturing facility is a measure of the progress we ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
Breaking Medicine Technology:
(Date:6/28/2017)... Cincinnati, OH (PRWEB) , ... June 28, 2017 ... ... residents of Hamilton County and the surrounding regions access to insurance assistance and ... conjunction with Matthew 25: Ministries to assist families in the region facing financial ...
(Date:6/27/2017)... ... 27, 2017 , ... Nearly 70 percent of consumers now ... by the American Society for Dermatologic Surgery (ASDS). , The ... considering a cosmetic medical procedure has doubled since 2013. , “Cosmetic procedures continue ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Congressional Budget Office (CBO) projects ... replace the 2010 Patient Protection and Affordable Care Act (ACA), would result in 22 ... expected under current law. , More than 20 million Americans have gained health insurance ...
(Date:6/27/2017)... Bradley, Illinois (PRWEB) , ... June 27, 2017 , ... ... Ill. were featured in a video designed to encourage lawmakers to protect ... and National Center for Assisted Living (AHCA/NCAL), highlights the story of Chuck and Cathy ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... P. Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process ... Urbanski offered their experience in these popular periodontal procedures. Drs. Toback and Urbanski ...
Breaking Medicine News(10 mins):